%0 Journal Article
%T Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones
as Allosteric and Mutant Specific Inhibitors of IDH1
%A Arne Mueller
%A B. Barry Tour¨¦
%A Brant Firestone
%A Fallon Lin
%A Fan S. Yang
%A Gang Liu
%A Gregg Chenail
%A Ina Dix
%A John Giraldes
%A Joseph D. Growney
%A Julia Dooley
%A Julian R. Levell
%A Kelly Slocum
%A Liping X. Zhou
%A Michael D. Jones
%A Ming Xu
%A Pascal D. Fortin
%A Raviraj Kulathila
%A Raymond Pagliarini
%A Remi Terranova
%A Simon van der Plas
%A Thomas Caferro
%A Trixie Wagner
%A Troy Smith
%A Ty Gould
%A Viraj Tyagi
%A Xiaoling Xie
%J Archive of "ACS Medicinal Chemistry Letters".
%D 2017
%R 10.1021/acsmedchemlett.6b00334
%K Mutant IDH1 inhibitor
%K allosteric inhibition
%K 2-HG
%K preclinical in vivo activity
%K 3-pyrimidin-4-yloxazolidin-2-one
%K chirality-defined potency
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304300/